• Home
  •  / Verona Pharma
Verona Pharma

Verona Pharma


$40 M

FY, 2021

Market Capitalization

£228 M


Verona Pharma Summary

Company summary

Verona Pharma plc is a United Kingdom-based bio-pharmaceutical company. The Company is engaged in developing drugs for the treatment of chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Its program is RPL554, an inhaled, dual phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4) inhibitors, as a nebulized treatment for patients in hospital with acute exacerbation of chronic obstructive pulmonary disease (COPD) and cystic fibrosis. RPL554 has completed two double-blind placebo controlled randomized Phase II b studies of RPL554: one in mild to moderate asthma and another in mild to moderate COPD. Its other products include VRP700 and NAIPs. VRP700 is an anti-tussive (cough) drug and has completed a Phase II trial. The Company's subsidiaries include Rhinopharma Limited and Verona Pharma Inc.
London, GB | view all locations
Cybersecurity rating
ESG rating
out of 100 | View all ESG data

Key people

  • David Ebsworth

    David Ebsworth, Chairman

    • Ken Cunningham

      Ken Cunningham, Non-Executive Director

      • Martin Edwards

        Martin Edwards, Non-Executive Director

      • David Zaccardelli

        David Zaccardelli, Director, President and Chief Executive Officer

      LocationsView all

      3 locations detected

      • London HQ

        United Kingdom

        3 More London Riverside

      • Raleigh, NC

        United States

        8045 Arco Corporate Dr

      • Cardiff, Wales

        United Kingdom

        One Central Square

      Verona Pharma Financials

      Summary financials

      Net income (Q2, 2022)
      Cash (Q2, 2022)
      EBIT (Q2, 2022)
      Enterprise value

      Footer menu